





2024

EDITORIAL CALENDAR

	JANUARY	FEBRUARY	MARCH	APRIL	MAY	JUNE
Special Editions	Special Launch Issue (see page 2 for details)	Delivery & Formulation			mRNA Processing & Analysis	
Monthly content focus			 mRNA: Processing	 mRNA: Regulation		 mRNA: Engineering and design
			 Oligonucleotides: Targeting & delivery	 Oligonucleotides: Manufacturing		 Oligonucleotides: Analytics & CMC
			 pDNA: Analytics & CMC	 pDNA: Processing		 pDNA: Supply chain
			 Formulation & delivery: Regulation	 Formulation & delivery: LNPs		 Formulation & delivery: Stability
	JULY	AUGUST	SEPTEMBER	OCTOBER	NOVEMBER	DECEMBER
Special Editions			Oligonucleotide Manufacture & Supply Chain			Plasmid DNA
Monthly content focus	 mRNA: Preclinical & translational tools	 mRNA: Clinical development strategy		 mRNA: Processing	 mRNA: Analytics & CMC	
	 Oligonucleotides: Clinical development strategy	 Oligonucleotides: Emerging modalities		 Oligonucleotides: Conjugated oligos	 Oligonucleotides: Research, preclinical and translational R&D strategy	
	 pDNA: Analytics & CMC	 pDNA: Processing		 pDNA: Next-generation technologies	 pDNA: Regulation	
	 Formulation & delivery: Guide RNA innovation	 Formulation & delivery: Extracellular vesicles		 Formulation & delivery: LNPs	 Formulation & delivery: RNA/DNA delivery of genome editing platforms	

Contact Nicola McCall on +44 1732 463215 or n.mccall@insights.bio to discuss thought leadership and lead generation opportunities

2024

EDITORIAL CALENDAR

Spotlights summary

JANUARY

FEBRUARY

MARCH

Delivery & Formulation

Contributors include:
Dr Naim Nazef, Takeda;
Dr Yupeng Chen,
University of Connecticut;
Professor Colin Pouton
and **Dr Angus Johnston**,
Monash University

Contributors include:
Dr Peter Oliver, Nucleic Acid
Therapy Accelerator (NATA) and
University of Oxford;
Dr Sritama Bose, NATA

APRIL

MAY

JUNE

mRNA Processing & Analysis

Contributors include:
Dr John Counsell, University
College London;
Dr Julien Couture-Senecal,
Azane Therapeutics

Contributors include:
Dr Andrew Varley, The
University of British Columbia

JULY

AUGUST

SEPTEMBER

Innovation in Oligonucleotide Manufacture & Supply Chain

OCTOBER

NOVEMBER

DECEMBER

Plasmid DNA

NUCLEIC ACID INSIGHTS SPECIAL LAUNCH EDITION JANUARY 2024

The inaugural edition of *Nucleic Acid Insights* features a wide variety of stakeholders from across the nucleic acids space sharing their perspectives on recent progress, current challenges, and future directions in the field.

Confirmed contributors to this special edition include:

Floris Engelhardt, CEO, Kano Therapeutics

Jane A. Healy, VP, Head of Oncology Early Clinical Development,
Merck & Co, Inc.

Robert Langer, David H. Koch Institute Professor, MIT

John Lewis, CEO, Entos Pharmaceuticals

Paolo Martini, CSO, International Therapeutics Research Centers, Founder
of Moderna Rare Diseases, Moderna

Chris Mason, Professor of Cell and Gene Therapy, Advanced Centre for
Biochemical Engineering, University College London

Myriam Mendila, Chief Development Officer, Curevac

Nizar Saad, Assistant Professor, The Ohio State University Medical School;
Department of Pediatrics, Nationwide Children's Research Institute

Matthew Scholz, CEO, Oisin Biotechnologies

Hartaj Singh, Managing Director, Oppenheimer & Co. Inc.

2024

EDITORIAL CALENDAR Spotlight details

Nucleic Acid Insights' Spotlights provide you with fantastic opportunities to:

- Educate your target market** about your company's expertise, capabilities and experience
- Share your latest data** with organisations looking for partners and service providers in your field
- Profile your executives and scientists** as thought-leaders and KOLs
- Generate qualified leads** from across the global sector
- Increase awareness** of your company's role in cell and gene therapy R&D and manufacture.

Each spotlight will comprise:

- Peer-reviewed Reviews and Expert Insight articles** written by leading experts in the field
- Webinars**, featuring industry speakers and sponsors discussing key topics specific to the Spotlight
- Podcast, written and video interviews** with key opinion leaders
- On demand **roundtable discussions**

FEB

Delivery & Formulation

- ▶ Tissue-specific targeting – which approaches are proving to be optimal?
 - ▶ How and where can we move beyond the liver ?
- ▶ Nanoparticles (lipid and polymer)
 - ▶ Overcoming freedom to operate barriers
- ▶ Extracellular vesicles
- ▶ Chemical conjugates
- ▶ Exploring novel techniques for oligonucleotide formulation / encapsulation
- ▶ Optimizing RNA stability
- ▶ Addressing toxicity issues in DNA delivery
- ▶ Advancing non-temperature-dependent formulation

MAY

mRNA Processing & Analysis

- ▶ How to reduce CoGs?
- ▶ Process optimization
 - ▶ How to drive improvements in scalability and consistency?
 - ▶ What are advances in mRNA manufacturing automation and the application of single-use technologies delivering in practice?
 - ▶ How best to address potential downstream purification issues in upstream processing?
 - ▶ Needs and opportunities in downstream processing
- ▶ Analytical innovation: recent breakthroughs and remaining needs

SEP

Innovation in Oligonucleotide Manufacture & Supply Chain

- ▶ How to address the growing shortfall in supply of GMP-grade synthesized oligos?
- ▶ What progress in enhancing capabilities while controlling costs in oligo synthesis?
- ▶ How to improve the sustainability of oligo manufacturing?

DEC

Plasmid DNA

- ▶ How to address the ongoing supply bottleneck?
 - ▶ Improving and accelerating plasmid manufacturing processes
- ▶ How great a threat do synthetic approaches really present to pDNA?
- ▶ Improving pDNA processing productivity, quality, consistency, and cost effectiveness
 - ▶ Single-use systems
 - ▶ What are the 'must-do's' to ensure pDNA quality (both for use as a starting material and as a drug product)?